BizNis Africa
Latest News
WhereIsMyTransport to host CONNECT Hackathons across Africa
WhereIsMyTransport has partnered with Facebook for Developers to host the CONNECT...
World Economic Forum 2018 – impact for South African Investors
It’s that time of year again where more than...
Business acumen key for growing entrepreneurs in South Africa
Running a successful business, especially Small, Medium and Micro...
Top property trends 2018 in South Africa
The year 2017 has been a challenging year for...
JSE continues to lag behind global markets
Over the past five years, local markets returned just...
Burkina Faso hosts first Pan-African democratic governance meeting
Burkina Faso hosted the first Pan-African meeting designed to...
MTN South Africa invested ZAR30 billion in network infrastructure
MTN has invested more than ZAR30 billion (about $2.4...
IFC named top investor in Partech Africa €100 million VC fund
IFC, a member of the World Bank Group, has...
Ramaphosa talks tough against corruption ahead of WEF
South Africa’s deputy president and new leader of the...
Energy stakeholders in Africa to discuss investments opportunities
The Powering Africa: Summit will return for a fourth...

Dr Karsten Wellner, Ascendis Health CEO

Ascendis Health announced on 18 December 2017, the results of a fully underwritten renounceable rights offer to raise ZAR750 million.

The proceeds will be used to settle EUR50m of the deferred vendor consideration payment owed to the sellers of Remedica Holdings, an international pharmaceutical business acquired in 2016, at a discount. Ascendis and the sellers of Remedica Holdings have agreed that Ascendis will settle EUR46.2m in advance of the due date.

The rights offer was priced at ZAR20.00 per share, being a 5% premium to the market price at the time of announcing the rights offer.

The rights offer was fully underwritten by long-term investment company Coast2Coast Capital, who effectively took up 26% of the rights offer shares in terms of their rights allocation and a further 73% of the rights offer shares in terms of the underwrite.

“The underwriting of the rights offer by our major shareholder, Coast2Coast Capital, who not only followed their rights but took up the remaining shares in terms of the underwrite indicates confidence in Ascendis. This confidence is reinforced by the recent purchasing of shares by management and directors on the market. The early settlement of the deferred vendor payment will help in degearing the balance sheet and supports our aims in achieving our optimal capital structure,” comments Dr Karsten Wellner, Ascendis Health CEO. 

Leave a Reply

Ver peliculas online
%d bloggers like this: